分组1 - Chewy reported quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share, and showing a decline from $0.28 per share a year ago, resulting in an earnings surprise of -3.57% [1] - The company posted revenues of $3.26 billion for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 0.27%, and showing a slight increase from $3.25 billion year-over-year [2] - Chewy shares have declined approximately 29.1% since the beginning of the year, contrasting with the S&P 500's decline of 4.2% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.41 on revenues of $3.36 billion, and for the current fiscal year, it is $1.56 on revenues of $13.58 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the bottom 34% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

分组1 - TELA Bio, Inc. reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and improved from a loss of $0.23 per share a year ago, resulting in an earnings surprise of +11.11% [1] - The company posted revenues of $20.87 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.62%, but showing an increase from $17.65 million in the same quarter last year [2] - TELA Bio shares have declined approximately 29.7% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $21.2 million, and for the current fiscal year, it is -$0.49 on revenues of $92.7 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, indicating that the industry outlook may negatively impact stock performance [8]

分组1 - Ondas Holdings Inc. reported a quarterly loss of $0.39 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -609.09% [1] - The company posted revenues of $30.11 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 7.54%, and showing a substantial increase from $4.13 million in the same quarter last year [2] - Over the last four quarters, Ondas Holdings has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] 分组2 - The stock has gained approximately 3.1% since the beginning of the year, contrasting with a 5% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $28.55 million, and for the current fiscal year, it is -$0.17 on revenues of $175.02 million [7] - The Zacks Industry Rank indicates that the Wireless National sector is currently in the bottom 20% of over 250 Zacks industries, which may negatively impact stock performance [8]

分组1 - FiscalNote Holdings, Inc. reported a quarterly loss of $0.66 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.67, and an improvement from a loss of $1.2 per share a year ago, resulting in an earnings surprise of +1.01% [1] - The company posted revenues of $22.2 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.84%, and down from $29.47 million in the same quarter last year [2] - FiscalNote Holdings, Inc. shares have declined approximately 35.4% since the beginning of the year, contrasting with the S&P 500's decline of 3.2% [3] 分组2 - The earnings outlook for FiscalNote Holdings, Inc. is uncertain, with current consensus EPS estimates of -$0.59 on revenues of $22.62 million for the coming quarter and -$1.83 on revenues of $92.81 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Technology Services sector is currently in the bottom 23% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Core Viewpoint - 4D Molecular Therapeutics, Inc. reported quarterly earnings of $0.43 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.53 per share, marking an earnings surprise of +180.75% [1] Financial Performance - The company posted revenues of $85.09 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 147.86%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$1.05 on revenues of $0.03 million, and for the current fiscal year, it is -$3.40 on revenues of $25.7 million [7] Stock Performance - 4D Molecular Therapeutics shares have increased by approximately 14.8% since the beginning of the year, while the S&P 500 has declined by 1.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Drugs industry is currently in the top 36% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Another company in the same industry, IGC Pharma, Inc., is expected to report a quarterly loss of $0.02 per share, with revenues projected to be $0.19 million, down 26.9% from the year-ago quarter [9]

Core Insights - uCloudlink Group Inc. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, and compared to a loss of $0.04 per share a year ago, indicating a negative earnings surprise of -33.33% [1] - The company posted revenues of $22.17 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 3.61%, and down from $25.96 million in the same quarter last year [2] - The stock has lost about 0.6% since the beginning of the year, while the S&P 500 has declined by 1.9% [3] Earnings Outlook - The earnings outlook for uCloudlink Group is uncertain, with current consensus EPS estimates at -$0.04 on revenues of $18.5 million for the coming quarter, and -$0.05 on revenues of $90.5 million for the current fiscal year [7] - The estimate revisions trend for the company was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Internet - Software industry, to which uCloudlink Group belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment and stock performance [5]

Core Viewpoint - HealthEquity reported quarterly earnings of $0.95 per share, exceeding the Zacks Consensus Estimate of $0.89 per share, and showing an increase from $0.69 per share a year ago [1] Earnings Performance - The earnings surprise for the quarter was +7.09%, with a previous quarter surprise of +12.22% when actual earnings were $1.01 compared to an expected $0.90 [2] - Over the last four quarters, HealthEquity has consistently surpassed consensus EPS estimates [2] Revenue Performance - The company posted revenues of $334.59 million for the quarter, surpassing the Zacks Consensus Estimate by 0.52%, and an increase from $311.82 million year-over-year [3] - HealthEquity has also topped consensus revenue estimates in the last four quarters [3] Stock Performance and Outlook - HealthEquity shares have declined approximately 14.1% since the beginning of the year, while the S&P 500 has decreased by 2.1% [4] - The company's future stock performance will largely depend on management's commentary during the earnings call [4] Earnings Outlook - Current consensus EPS estimate for the upcoming quarter is $1.15 on revenues of $355.32 million, and for the current fiscal year, it is $4.58 on revenues of $1.39 billion [8] Industry Context - The Medical Services industry, to which HealthEquity belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [9]

分组1 - DocGo Inc. reported a quarterly loss of $0.53 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.1, and compared to earnings of $0.04 per share a year ago, indicating an earnings surprise of -457.90% [1] - Over the last four quarters, the company has consistently failed to surpass consensus EPS estimates, while Motion Acquisition, another company in the Zacks Medical Services industry, reported revenues of $74.94 million, exceeding the Zacks Consensus Estimate by 6.14% [2] - Motion Acquisition shares have declined approximately 25.1% since the beginning of the year, contrasting with the S&P 500's decline of 3.1% [3] 分组2 - The future performance of Motion Acquisition's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, which includes current consensus earnings expectations for upcoming quarters [4] - The estimate revisions trend for Motion Acquisition was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $69.1 million, and -$0.18 on revenues of $290.16 million for the current fiscal year [7] 分组3 - The outlook for the Medical Services industry can significantly impact stock performance, with the industry currently ranking in the bottom 42% of over 250 Zacks industries [8] - Icon PLC, another company in the same industry, is expected to report quarterly earnings of $3.30 per share, reflecting a year-over-year change of -3.8%, with revenues anticipated to be $2 billion, down 1.9% from the previous year [9]

分组1 - The Beauty Health Company (SKIN) reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and improved from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company posted revenues of $82.4 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.42%, although this represents a decline from year-ago revenues of $83.5 million [2] - Beauty Health has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 19.1% since the beginning of the year, compared to a 1% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $69.33 million, and for the current fiscal year, it is -$0.18 on revenues of $302.8 million [7] - The Zacks Industry Rank indicates that the Medical Services sector is in the bottom 43% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

分组1 - Exagen Inc. reported a quarterly loss of $0.2 per share, consistent with the Zacks Consensus Estimate, and the same loss as the previous year [1] - The company posted revenues of $16.63 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.62% and showing an increase from $13.65 million year-over-year [2] - Exagen shares have declined approximately 44.4% since the beginning of the year, contrasting with the S&P 500's decline of 0.7% [3] 分组2 - The earnings outlook for Exagen is uncertain, with current consensus EPS estimates at -$0.15 for the coming quarter and -$0.48 for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 38% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] 分组3 - The estimate revisions trend for Exagen was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]